Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA)
A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy
Sponsor: UNICANCER
This PHASE2 trial investigates Triple Negative Breast Neoplasms and is currently actively recruiting participants. UNICANCER leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE2
Phase: PHASE3 → PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2023 — Jun 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Avignon, France , Bayonne, France , Besançon, France , Bordeaux, France , Caen, France , Dijon, France , La Roche-sur-Yon, France , Lille, France , Lyon, France and 10 more locations